ABSTRACT. Patients with mevalonate kinase deficiency suffer from psychomotor retardation, ataxia with progredient cerebellar atrophy, and myopathy. The pathophysiology of the disease remains unclear. The mevalonate kinase product, cholesterol, is within the normal range in patient plasma and fibroblasts. In search of the pathophysiology of this disorder, another mevalonate kinase product, ubiquinone-10, was studied. The concentrations of ubiquinone-10 in patient plasma (n = 6) and ubiquinol-10 in patient LDL (n = 2) and the synthesis of ubiquinone-10 in patient fibroblasts (n = 4) were determined. After oxidative modification of LDL by copper in vitro, the concen- range = 564-809 pg/L; p < 0.005) were decreased. 1 n . c~~ samples of two affected siblings, the concentration of ubiquinol-10 and the resistance to oxidation in vitro were found decreased during intercurrent patient crisis condition. In patient fibroblasts (median = 533 dpm/mg protein, range = 399-1 047 dpmlmg protein) versus controls (median = 40 731 dpm/mg protein, range = 12 774-54 739 dpmlmg protein), the synthesis of ubiquinone was found to be decreased. We conclude that mevalonate kinase deficiency leads to a decreased synthesis of ubiquinone-10 and that ubiauinone-10 deficiencv is res~onsible for the clinical progresiion of this disease characterized by increased lipid peroxidation, cerebellar atrophy, cataract development, and myopathy with increased creatine kinase activity. (Pediatr Res 34: 129-133, 1993) Abbreviations HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A Rf, relative electrophoretic mobility 12 (4). The enzyme mevalonate kinase is involved in the synthesis of cholesterol and several nonsterol isoprenes such as ubiquinone-10. also known as coenzyme Qlo (Fig. 1) ( 1, 5).
Clinical manifestations begin in early childhood and progress with great variability of severity and organ involvement ( 1, 6-9). In 10 patients. we observed psychomotor retardation ( I 0 of 10). myopathy (nine of lo), ataxia (five of nine), failure to thrive (nine of 1-0). hepatosplenomegaly (six of 10). dysmorphic features (five of 10). and cataracts (three of 10). Neuroradiolo~c and iostmortem investigations revealed extensive cerebellar atrophy (five of nine) with a marked progression during the first years of life. Creatine kinase activity in plasma was frequently increased (six of nine). Most patients suffered from episodic crises characterized by fever, nausea, diarrhea, and weakness. Some patients exhibited mucocutaneous rashes, edema, and arthritis.
In patients with mevalonate kinase deficiency, the concentrations of mevalonate in plasma and urine are markedly elevated ( 1. 3). Despite the mevalonate kinase deficiency, cholesterol concentration in patient serum ( I , 2, 7. 9) and fibroblasts ( 10) is normal or only slightly reduced, and the pathophysiology of this disease remains unclear.
Therefore, we investigated another important product of mevalonate kinase, ubiquinone-I0 and ubiquinol-10, the reduced form of ubiquinone-10, which have a protective effect on the antioxidant tu-tocopherol (vitamin E) ( 1 1 -1 3). Ubiquinol-I0 has been described as one of the Dotent antioxidants within LDL (13). To test whether the ubihuinone-10 concentration is decreased in patients with mevalonate kinase deficiency, we determined ubiquinone-I0 concentrations in plasma aswell as the synthesis of ubiquinone-I0 in cultured fibroblasts. Ubiquinol-I0 concentration and antioxidant capacity of LDL samples of two patients were also investigated.
MATERIALS AND METHODS
Putients a n d .statistical unuly.sis. Investigations were carried out on samples from nine patients (four boys, five girls; median age = 2 y, range = 0.3-7 y). as listed in Table 1 column (150 x 4 mm, 5 pm; Nucleosil, France) (14) . Ubiquinone-10 was detected by UV light absorption (A = 275 nm) and quantified using an external standard (ubiquinone-10, Sigma Chemical Co., Deisenhofen, Germany) ( Table 2 and 3) . a-Tocopherol and ubiquinol-10 in LDL. a-Tocopherol in LDL from two affected siblings (patients AA and AB, Table 1 ; one boy, one girl; 5 and 6 y, respectively) and from healthy children (five boys, three girls; median age = 7 y, range = 5-9 y) was measured by HPLC (1 5). Quantities as low as 0.02 pg (46 pmol/ injection) could be detected (Table 3 ; Fig. 2 ).
Ubiquinol-10 concentrations in lipid extracts ( 16) from LDL samples of the two affected siblings (AA and AB, Table 1 ) and of healthy children (two boys, three girls; median age = 5 y, range = 5-14 y; Table 3 ) were determined by reverse-phase HPLC using a Lichrospher RP-18 column (150 x 4 mm, 5 pm; E. Merck, Darmstadt, Germany) and a Hewlett-Packard 1049A Electrochemical Detector (amperometric mode; Hewlett-Packard, Andover, MA) set to a potential of 0.8 V (0.5 pA full scale). * Patients AA, AB. BC, and C (see Table I ).
Patient vs control values. p < 0.002; Mann-Whitney U test. $ Patients BA and BB (see Table 1 ). The mobile phase consisted of ethano1:methanol = 1:l with 2 g/L LiOsCl and 1 g/L acetic acid (E. Merck). It was delivered by a Merck L6000 HPLC pump with a flow rate of 1 mL/min. For data acquisition, a Merck D2500 Integrator was used. Quantification was performed by external standardization. The ubiquinol-10 standard was freshly prepared from ubiquinone-10 (bovine heart, Sigma Chemical Co.) as described by Lang et a/. (17) . Quantities as low as 0.4 pmol/injection (i.e. 4 pmol/mg LDL cholesterol) could be detected.
Ubiquinone and dolichol biosynthesis inJibrohlasts. Skin fibroblasts (five to 14 passages) from patients with mevalonate kinase deficiency (three boys, one girl; patients AB, D, E, and F; 0.3-2 y of age; Table 1 ) and of three healthy age-and gender-matched controls were investigated. The ubiquinone and dolichol synthesis was estimated by measuring the metabolic flux of R-[5-'HImevalonolactone (New England Nuclear, Boston, MA) through the mevalonate pathway (1, 5) in the presence of lovastatin (1 8). Radiolabeled intermediates were separated by phenol:chloroform and petroleum ether extraction (18, 19) . Deviating from the method originally described by Maltese and Aprille (18) , cells were incubated for 21 h (37'C), and delipidated FCS was used Table I ).
in a final concentration of 10% (2). After two-dimensional, thinlayer chromatography of concentrated petroleum ether extracts, products were localized by iodine staining and quantified by liquid-scintillation spectrometry. In our experimental assay, discrimination of the dolichol region from the ubiquinone region was not possible.
Oxidative modiJication of LDL. LDL from two affected siblings (one boy, one girl, patients AA and AB, 5 and 6 y of age, respectively; Table 1 ) and from healthy children (five boys, three girls; median age = 7 y, range 5-9 y) were isolated by densitygradient centrifugation (20) . Blood samples were obtained from the siblings during a crisis condition with fever, nausea, diarrhea, and weakness. A second sample was taken from one sibling without such a crisis condition (patient AB in Table I ). Further blood samples were taken after 5 mo of oral substitution with atocopherol (30 mg/kg body wt/d).
LDL suspension was diluted by PBS (without Ca" and Mg", pH 7.3; Sigma Chemical Co.) to reach a final LDL cholesterol concentration of 0.85 mg/mL (Cholesterin Monotest, Boehringer Mannheim, Mannheim, Germany). Oxidative modification of LDL was achieved by incubation (37°C) of the LDL suspension in serial dilutions of Cu++ (CuS04, M, 249.68; E. Merck) for 18 h as indicated on the horizontal axis in Figure 2 (20, 2 1) .
Fatty acids of LDL were determined by capillary gas chromatography (20) (Fig. 2) . Rf of LDL and oxidatively modified LDL was assessed on 0.83% agarose gels (20) (Fig. 2) . The Rf value is defined as the distance of the LDL spot center from the starting point divided by the according distance of the bromophenolblue-stained solvent front.
Mevalonic acid. Mevalonate concentrations in plasma samples were determined using a stable isotope dilution assay and capillary gas chromatography-mass spectrometry with both electron impact and ammonia chemical ionization (3).
RESULTS
In plasma samples of six patients (patients AA, AB, BA, BB, BC, and C; Table 1 ) with mevalonate kinase deficiency, the concentration of mevalonic acid was highly increased (Table 2) . In four (patients AA, AB, BC, and C; Table I ) of these six patient plasma samples, ubiquinone-10 concentration was decreased, and creatine kinase activity was increased (Table 2) . In two samples, plasma ubiquinone-I0 concentration and creatine kinase activity were within the normal range (Table 2 ). These two normal plasma samples were obtained from two affected siblings (patients BA and BB. Table 1 ) who had a third affected sibling with pathologic plasma values (patient BC; Table 1 ).
Concentrations of ubiquinone-10 in plasma and a-tocopherol in LDL were determined in two siblings (patients AA and AB; Table 1 ) with mevalonic aciduria under different clinical and thera~eutic conditions (Table 3) . Ubiauinone-10 and a-toco~h-erol concentrations increased under si~ultaneously administered oral substitution with ubiquinone-10, a-tocopherol, and ascorbic acid (Table 3) .
Ubiquinol-10 was determined in LDL samples taken from the two sibling patients (patients AA and AB; Table 1 ) only after treatment with ubiquinone-10, a-tocopherol, and ascorbic acid. One patient (patient AB; Table 1 ) was in an episodic crisis condition, whereas his sister (patient AA; Table I ) was not. In the female sibling, who was not in a crisis condition, ubiquinol-10 in LDL was elevated in response to the oral ubiquinone-I0 substitution. However, the girl's brother, who received the identical oral treatment with ubiquinone-I0 but who suffered from a crisis condition, had a markedly decreased LDL-ubiquinol-10 level when compared with his sister or with control values (Table  3) .
Quantification of the common chromatography region of dolichol and ubiquinone revealed a considerably lower biosynthetic activity in patient fibroblast extracts (median = 533 dpm/mg protein, range = 399-1 047 dpm/mg protein; n = 4: patients AB.
D. E, and F; LDL was isolated and oxidatively modified by copper (CuS04) incubation in vitro (Fig. 2) . In LDL samples isolated from healthy control children (n = 8), increasing concentrations of CuS04 resulted in continuously decreasing concentrations of a-tocopherol (values of native LDL versus respective values of LDL after oxidation by 3.8 pM Cu": p < 0.03; Fig. 2 ) and polyunsaturated fatty acids and increasing electrophoretic mobility of the LDL on agarose gel. At the copper concentration of 3.8 pM Cu++, the SD of determined values increased because some of the control LDL samples were already oxidatively modified, whereas other control LDL samples with a greater antioxidant capacity were not (Fig. 2) . These results clearly indicate a decrease in antioxidant capacity of LDL in controls, which is followed by the consumption of a-tocopherol, lipid peroxidation, and thus the peroxidative degradation of polyunsaturated fatty acids (2 1 ). The increased Rf of LDL on agarose gel indicates increased negative surface charge of the oxidatively modified LDL, presumably due to a modification of apo B (2 1).
In the two patient siblings (patients AA and AB; Table 1 ) with mevalonic aciduria, LDL samples were obtained during an episodic crisis condition with fever, nausea, diarrhea, and weakness (Fig. 2) . A decrease in the content of polyunsaturated fatty acids was observed in these samples after incubation in only very low concentrations of Cu" (0.9 and 1.9 pM; Fig. 2 ). a-tocopherol content of one LDL sample (patient AA; Table 1) dropped from a normal level to undetectable values after incubation in only 0.9 pM Cu++ (Fig. 2) . In one of the two patients, blood was obtained for LDL analysis when the patient was out of crisis condition (patient AB; Table 1 ). Substantial LDL oxidation was observed at 3.8 pM Cu" (Fig. 2) , similar to normal control values.
After oral substitution of the two patient siblings (patients AA and AB; Table I ) with a-tocopherol (30 mg/kg body weight/d over 5 mo), the susceptibility of patient LDL to peroxidative damage was normalized (Fig. 2) . Under this therapy, a-tocopherol concentration of patient LDL was triple normal values. Nevertheless, LDL-associated a-tocopherol was rapidly con-sumed by challenge of LDL with increasing doses of Cu" (Fig. to an unstable ubiquinol-I0 concentration in LDL of mevalonic  2) . aciduria patients. This notion is supported by the demonstration that n-tocopherol levels were within lower normal ranges in DISCUSSION native LDL of patients during and out of crisis condition (Table  3) , but decreased more rapidly than in controls during oxidative Ubiquinone-10 concentration was found decreased in four modification of an LDL sample taken from a patient (patient (patients AA, AB, BC, and C; Table 1 ) of six patient plasma AA; Table I ) during crisis condition (Fig. 2) . Moreover, the samples (Table 2) , suggesting liver involvement (22, 23) in mev-mhanced ff-tocopherol concentrations in LDL samples taken alonate kinase deficiency. This is supported by the above-men-from patients (AA and AB; Table I ) treated with vitamin E and tioned clinical sign of hepatosplenomegaly and by the single the sharp decrease of n-tocopherol concentration in these LDL observation that ubiquinone-I0 concentration was also decreased ~amples under oxidation (Fig. 2) indicate an increased consumpin liver tissue ( 1 1.9 wg ubiquinone-lO/g wet weight versus 17.1 tion of n-toco~herol in patient LDL. probably as a second step and 17.2 wg/g in two gestational age-matched controls, respec-after ubiquinol-lo consumption ( 13). Unfortunately, we lack tive]y) obtained from an aborted fetus ( 19 wk of gestation) with data on ubiquinol-10 concentration in LDL samples in vitro (Fig.  meValonate kinase deficiency (1, 3) . The data indicate a Ubiqui-2) as well as in native LDL samples P.\-vivo of untreated patients none-10 deficiency in patients with meValonate kinase defi- (Table 3) . We could find a drastic decrease of ubiquinol-I0 ciency.
concentration in LDL taken from one patient (patient AB: Table  Funher support for this notion comes from the finding of a 1) during a crisis condition, despite oral substitution with ndecreased ubiquinone-10 and dolichol synthesis in cultured skin tocopherol, ubiquinone-10, and ascorbic acid, whereas the ubifibroblasts isolated from four patients with meValonate kinase q~i n o l -l o concentration in LDL taken from an affected sibling deficiency (patients AB, D, E. and F; Table 1 ). In our experi-(patient AA; Table 1 ) under identical conditions, but out of such mental assay, discrimination of the dolichol region from the a crisis condition. was not decreased compared with control ubiquinone region was not possible. However, the data suggest a values (Table 3) . We assume that a decrease of ubiquinol-10 is primary ubiquinone-10 deficiency due to meValonate kinase involved in the pathophysiology of the episodic crises that are a deficiency (Fig. I) . This is in contrast to findings in mitochondria1 most characteristic feature of the disease. Kearns-Sayre syndrome with similar clinical signs and similarly decreased plasma ubiquinone-I0 concentration but normal ubi-..icknowledgmmls. The authors thank B. Sehringer-Mansour quinone-I0 synthesis in fibroblasts (24) . and I. Wernicke. Hamburg, Germany, and C. K. Seppel. HeiConsiderable amounts of ubiquinone-I0 have been found in delberg, Germany. for excellent technical assistance, and J. Knishuman brain cortex and cerebellum (25) . Ubiquinols are potent pel, Hamburg, Germany, for his language advice. antioxidants in synaptosomes from brain gray matter (26) , and investigations on rodents revealed that the cerebellum is the alonate kinase in the pathway (Fig. I) Table I ) of the two 13. Stocker R. Bowry VW. Frei B 1991 Ubiquinol-I0 protects human low density affected siblings out of crisis condition (Fig. 2) . These results are lipoprotein more elficiently against lipid peroxidation than does n-tocophconsistent with the concept of ubiquinone-I0 deficiency leading erol. Proc Natl Acad Sci USA 88: 1646-1650
